Research Analysts Issue Forecasts for ITCI FY2025 Earnings

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Intra-Cellular Therapies in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the biopharmaceutical company will earn ($0.25) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Intra-Cellular Therapies' current full-year earnings is ($0.64) per share.

ITCI has been the topic of several other reports. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Baird R W cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Needham & Company LLC reiterated a "hold" rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Piper Sandler restated a "neutral" rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Intra-Cellular Therapies presently has an average rating of "Moderate Buy" and a consensus target price of $102.15.

Intra-Cellular Therapies Trading Up 0.5 %

Shares of Intra-Cellular Therapies stock traded up $0.65 during trading hours on Wednesday, reaching $127.15. 5,150,447 shares of the company's stock were exchanged, compared to its average volume of 7,081,260. The company has a 50 day moving average of $89.99 and a two-hundred day moving average of $81.30. The stock has a market cap of $13.48 billion, a P/E ratio of -146.21 and a beta of 0.70. Intra-Cellular Therapies has a fifty-two week low of $62.78 and a fifty-two week high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm's quarterly revenue was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.25) earnings per share.

Insider Buying and Selling

In related news, President Michael Halstead sold 22,869 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company's stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The disclosure for this sale can be found here. 2.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wasatch Advisors LP increased its stake in Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock worth $281,601,000 after acquiring an additional 130,351 shares during the last quarter. Bellevue Group AG increased its position in shares of Intra-Cellular Therapies by 0.6% in the third quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company's stock worth $181,873,000 after purchasing an additional 14,342 shares during the last quarter. State Street Corp raised its stake in Intra-Cellular Therapies by 3.1% in the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock valued at $136,017,000 after purchasing an additional 56,664 shares in the last quarter. Franklin Resources Inc. lifted its position in Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock valued at $129,463,000 after purchasing an additional 155,655 shares during the last quarter. Finally, Perceptive Advisors LLC grew its stake in Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company's stock worth $117,557,000 after buying an additional 661,052 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company's stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.